{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T13:52:22Z","timestamp":1791553942555,"version":"4.3.4"},"reference-count":19,"publisher":"Wiley","issue":"23-24","license":[{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA249279"],"award-info":[{"award-number":["R01 CA249279"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA256157"],"award-info":[{"award-number":["R01 CA256157"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R21 CA263950"],"award-info":[{"award-number":["R21 CA263950"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013132","name":"Combat Casualty Care Research Program","doi-asserted-by":"publisher","award":["HT9425\u201023\u20101\u20100393"],"award-info":[{"award-number":["HT9425\u201023\u20101\u20100393"]}],"id":[{"id":"10.13039\/100013132","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013132","name":"Combat Casualty Care Research Program","doi-asserted-by":"publisher","award":["HT9425\u201025\u20101\u20100623"],"award-info":[{"award-number":["HT9425\u201025\u20101\u20100623"]}],"id":[{"id":"10.13039\/100013132","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009210","name":"Food and Drug Administration","doi-asserted-by":"publisher","award":["U01FD007857"],"award-info":[{"award-number":["U01FD007857"]}],"id":[{"id":"10.13039\/100009210","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","award":["18CHAL02"],"award-info":[{"award-number":["18CHAL02"]}],"id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Statistics in Medicine"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>We propose a novel method that simultaneously determines the sample size for testing two survival probabilities at a pre\u2010specified time while guaranteeing Type I error control in both fixed and group\u2010sequential trial designs. Simulations across varying hypothesized differences, failure distributions, censoring proportions, and nominal powers demonstrate consistent performance, while interim analyses highlight maintained nominal Type I error control and increased power at each look relative to the standard binomial approach, regardless of the underlying failure time distribution or spending function. Importantly, our method is especially useful for evaluating survival outcomes at a fixed time in randomized trials where one treatment arm includes neoadjuvant therapy prior to surgery while the other involves surgery alone. Furthermore, it is advantageous when the proportional hazards assumption is not satisfied, as often occurs in immunotherapy trials with delayed or time\u2010varying treatment effects or crossing survival curves. The method is also applicable to randomized Phase II trials, where smaller sample sizes and the use of intermediate or surrogate time\u2010to\u2010event endpoints demand efficient data use and robust error control. We illustrate the approach with motivating examples in renal and prostate cancer. An accompanying R Shiny application enables investigators to compute sample sizes interactively, facilitating practical trial planning in diverse settings.<\/jats:p>","DOI":"10.1002\/sim.70750","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T13:27:55Z","timestamp":1791552475000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Group Sequential Sample Size for Comparing Two Survival Probabilities at a Specific Time Point"],"prefix":"10.1002","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4135-2777","authenticated-orcid":false,"given":"Susan","family":"Halabi","sequence":"first","affiliation":[{"name":"Department of Biostatistics and Bioinformatics Duke University School of Medicine  Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Bioinformatics Duke University School of Medicine  Durham North Carolina USA"},{"name":"Inflammation, Immunology &amp; Specialty Care Pfizer Inc.  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3452-9095","authenticated-orcid":false,"given":"Chenxi","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Bioinformatics Duke University School of Medicine  Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8925-555X","authenticated-orcid":false,"given":"Yuan","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Bioinformatics Duke University School of Medicine  Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,9]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1200\/JCO.20.00315","article-title":"Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High\u2010Risk Prostate Cancer","volume":"38","author":"Eastham J. A.","year":"2020","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_10_3_1","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/JCO.21.02051","article-title":"Dose\u2010Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle\u2010Invasive Bladder Cancer: Results of the GETUG\u2010AFU V05 VESPER Trial","volume":"40","author":"Pfister C.","year":"2022","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_10_4_1","doi-asserted-by":"crossref","first-page":"5035","DOI":"10.1200\/JCO.22.02852","article-title":"Randomized Phase III Study Comparing Neoadjuvant Chemotherapy Followed by Surgery Versus Chemoradiation in Stage IB2\u2010IIB Cervical Cancer: EORTC\u201055994","volume":"41","author":"Kenter G. G.","year":"2023","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_10_5_1","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.2307\/2533064","article-title":"Group Sequential Designs for Monitoring Survival Probabilities","volume":"52","author":"Lin D. Y.","year":"1996","journal-title":"Biometrics"},{"key":"e_1_2_10_6_1","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2307\/2530245","article-title":"A Multiple Testing Procedure for Clinical Trials","volume":"35","author":"O'Brien P. C.","year":"1979","journal-title":"Biometrics"},{"key":"e_1_2_10_7_1","doi-asserted-by":"crossref","first-page":"659","DOI":"10.2307\/2336502","article-title":"Discrete Sequential Boundaries for Clinical Trials","volume":"70","author":"Lan K. K. G.","year":"1983","journal-title":"Biometrika"},{"key":"e_1_2_10_8_1","volume-title":"Group Sequential Methods With Applications to Clinical Trials","author":"Jennison C.","year":"2000"},{"key":"e_1_2_10_9_1","volume-title":"Counting Processes and Survival Analysis","author":"Fleming T. R.","year":"1991"},{"key":"e_1_2_10_10_1","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1002\/sim.1771","article-title":"Sample Size Determination for Comparing Several Survival Curves With Unequal Allocations","volume":"23","author":"Halabi S.","year":"2004","journal-title":"Statistics in Medicine"},{"key":"e_1_2_10_11_1","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv156","article-title":"Milestone Survival: A Potential Intermediate Endpoint for Immune Checkpoint Inhibitors","volume":"107","author":"Chen T.","year":"2015","journal-title":"Journal of the National Cancer Institute"},{"key":"e_1_2_10_12_1","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1200\/JCO.1983.1.11.710","article-title":"Analysis of Survival by Tumor Response","volume":"1","author":"Anderson J. R.","year":"1983","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_10_13_1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1467-9868.2012.01030.x","article-title":"Group Sequential Tests for Delayed Responses","volume":"75","author":"Hampson L. V.","year":"2013","journal-title":"Journal of the Royal Statistical Society. Series B, Statistical Methodology"},{"key":"e_1_2_10_14_1","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1200\/PO.20.00301","article-title":"Randomized Phase II Study of 3 Months or 2\u2009Years of Adjuvant Afatinib in Patients With Surgically Resected Stage I\u2010III EGFR\u2010Mutant Non\u2010Small\u2010Cell Lung Cancer","volume":"5","author":"Neal J. W.","year":"2021","journal-title":"JCO Precision Oncology"},{"key":"e_1_2_10_15_1","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1001\/jamaoncol.2022.2666","article-title":"Log\u2010Rank Test vs MaxCombo and Difference in Restricted Mean Survival Time Tests for Comparing Survival Under Nonproportional Hazards in Immuno\u2010Oncology Trials: A Systematic Review and Meta\u2010Analysis","volume":"8","author":"Mukhopadhyay P.","year":"2022","journal-title":"JAMA Oncology"},{"key":"e_1_2_10_16_1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa2401726","article-title":"Adjuvant Pembrolizumab Versus Observation in Muscle\u2010Invasive Urothelial Carcinoma","volume":"392","author":"Apolo A. B.","year":"2025","journal-title":"New England Journal of Medicine"},{"key":"e_1_2_10_17_1","doi-asserted-by":"crossref","first-page":"8664","DOI":"10.1200\/JCO.2005.01.6071","article-title":"Disease\u2010Free Survival Versus Overall Survival as a Primary End Point for Adjuvant Colon Cancer Studies: Individual Patient Data From 20,898 Patients on 18 Randomized Trials","volume":"23","author":"Sargent D. J.","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_10_18_1","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jgo.2016.07.002","article-title":"Validity of Adjuvant! Online in Older Patients With Stage III Colon Cancer Based on 2967 Patients From the ACCENT Database","volume":"7","author":"Papamichael D.","year":"2016","journal-title":"Journal of Geriatric Oncology"},{"key":"e_1_2_10_19_1","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1001\/jamaoncol.2021.1371","article-title":"Three\u2010Year Follow\u2010Up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual ERBB2 Blockade in Patients With ERBB2\u2010Positive Breast Cancer: A Secondary Analysis of the TRAIN\u20102 Randomized, Phase 3 Trial","volume":"7","author":"Van der Voort A.","year":"2021","journal-title":"JAMA Oncology"},{"key":"e_1_2_10_20_1","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1200\/JCO.23.01535","article-title":"Radiographic Progression\u2010Free Survival and Clinical Progression\u2010Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone\u2010Sensitive Prostate Cancer","volume":"42","author":"Halabi S.","year":"2024","journal-title":"Journal of Clinical Oncology"}],"container-title":["Statistics in Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/sim.70750","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/sim.70750","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/sim.70750","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T13:27:58Z","timestamp":1791552478000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/sim.70750"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":19,"journal-issue":{"issue":"23-24","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1002\/sim.70750"],"URL":"https:\/\/doi.org\/10.1002\/sim.70750","archive":["Portico"],"relation":{},"ISSN":["0277-6715","1097-0258"],"issn-type":[{"value":"0277-6715","type":"print"},{"value":"1097-0258","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"2026-01-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70750"}}